Daewoong Pharmaceutical Receives Domestic Approval for 'Enblomet,' a Diabetes Drug Combined with Metformin

New Diabetes Drug Enblo to Be Combined with First-Line Diabetes Treatment
Scheduled for Release in September

Daewoong Pharmaceutical announced on the 14th that 'Enblomet Extended-Release Tablets 0.3/1000 mg (active ingredients: Inavogliflozin, Metformin Hydrochloride)' has obtained domestic product approval from the Ministry of Food and Drug Safety.

Daewoong Pharmaceutical SGLT-2 Inhibitor New Drug 'Enblo Tablets'. [Photo by Daewoong Pharmaceutical]

Enblomet Extended-Release Tablets are a two-drug combination of 'Inavogliflozin' and 'Metformin Hydrochloride.' It combines Daewoong Pharmaceutical's sodium-glucose co-transporter (SGLT)-2 inhibitor diabetes new drug 'Enblo Tablets' with the first-line diabetes treatment 'Metformin.' Enblomet Extended-Release Tablets have been approved as an adjunct to diet and exercise therapy to improve blood glucose control in patients with type 2 diabetes who are suitable for combination therapy of the two ingredients.

Diabetes patients who require combination therapy with two types of drugs can now take just one Enblomet Extended-Release Tablet, improving medication convenience. Daewoong Pharmaceutical plans to launch Enblomet Extended-Release Tablets in September.

Daewoong Pharmaceutical explained that Enblomet Extended-Release Tablets will be a meaningful treatment option amid the continuous increase in diabetes prevalence and the rising prescriptions of combination drugs. According to the '2022 Diabetes Fact Sheet' published by the Korean Diabetes Association, combination therapy steadily increased to about 80% by 2019. As demand for combination drugs is expected to grow, Daewoong Pharmaceutical emphasized that this product approval of Enblomet Extended-Release Tablets is a strategy to secure a leading position in the domestic market for SGLT-2 inhibitor diabetes treatments.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "It is a meaningful moment to receive product approval for Enblomet Extended-Release Tablets just one month after launching the first domestic SGLT-2 inhibitor new drug, Enblo Tablets." He added, "The domestic diabetes treatment market continues to see growing demand for combination drugs, and starting with Enblomet, we plan to continuously expand our combination drug lineup."

This content was produced with the assistance of AI translation services.